|
Ros-Madrid I, Febrero B, Cano-Marmol RP, Ruiz-Manzanera JJ, Segura P, Ferrer M, Rodriguez JM. Is Calcitonin at 6-12 Months an Appropriate Criterion to Define Cure in Medullary Thyroid Carcinoma? World J Surg. 2026 Aug 1. doi: 10.1002/wjs.70477. Online ahead of print. PubMed PMID: 42541766.
AÑO: 2026; IF: 2.5
|
42541766
|
Ros-Madrid I, Febrero B, Cano-Marmol RP, Segura P, Ferrer M, Rodriguez JM. Predicting Structural Progression-Free Survival After Surgery for Medullary Thyroid Carcinoma. World J Surg. 2026 Aug 8. doi: 10.1002/wjs.70524. Online ahead of print. PubMed PMID: 42569820.
AÑO: 2026; IF: 2.5
|
|
Ros-Madrid I, Febrero B, Cano-Marmol RP, Ferrer-Gomez M, Rodriguez JM. Predictors of Distant Metastasis in Patients with Medullary Thyroid Carcinoma. Cancers (Basel). 2025 Sep 30;17(19):3193. doi: 10.3390/cancers17193193. PubMed PMID: 41097721.
AÑO: 2025; IF: 4.4
|
|
Febrero B, Ros-Madrid I, Revilla-Nuin B, Abellan M, Ruiz-Manzanera JJ, Gomez J, Rodriguez JM. Could microRNA Analysis Help in the Management of Medullary Thyroid Cancer? Cancers (Basel). 2025 Feb 13;17(4):629. doi: 10.3390/cancers17040629. PubMed PMID: 40002224; PubMed Central PMCID: PMC11853104.
AÑO: 2025; IF: 4.4
|
|
Febrero B, Teruel E, Ros-Madrid I, Segura P, Rodriguez JM. The Influence of the Clinical, Therapeutic and Socio-Personal Profile on the Quality of Life of Patients With Multiple Endocrine Neoplasia Type 1. World J Surg. 2025 Apr;49(4):997-1005. doi: 10.1002/wjs.12522. Epub 2025 Mar 10. PubMed PMID: 40064591.
AÑO: 2025; IF: 2.5
|